Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| REGENXBIO Inc.RGNX · Entity 2211 | Chief Strategy & Legal Officer | August 01, 2026 | August 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
REGENXBIO Inc.
Report date August 01, 2026 · Filed August 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 205,968 |
Reported balance
After 2026-08-01 transaction · row 1
1 source rowRow 1 · 2026-08-01 · Tax withholding · Disposed 4,699 · Balance 205,968 F1: Represents shares of common stock withheld to pay taxes upon the vesting of restricted stock units originally granted to the reporting person on August 1, 2024. The number of shares withheld was determined based on the closing price of the issuer's common stock on August 1, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock withheld to pay taxes upon the vesting of restricted stock units originally granted to the reporting person on August 1, 2024. The number of shares withheld was determined based on the closing price of the issuer's common stock on August 1, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 09, 2018 Filed Apr 11, 2018 20:19 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $12.10 | $0.00 |
DisclosureSEC source: 0001562180-18-001886 · primarydocument.xml · derivative · entry 3 Christmas Patrick J. · CIK 0001521123 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,000 Underlying: Common Stock · 10,000 shares Expires 2026-08-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 125,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on August 18, 2017, and the balance vests in equal monthly installments over the 36 months thereafter while the optionee provides continuous service to the Issuer. Read SEC document |
| April 09, 2018 Filed Apr 11, 2018 20:19 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 10,000 | $34.00 | $340,000.00 |
DisclosureSEC source: 0001562180-18-001886 · primarydocument.xml · nonDerivative · entry 2 Christmas Patrick J. · CIK 0001521123 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,141 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| April 09, 2018 Filed Apr 11, 2018 20:19 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 10,000 | $12.10 | $121,000.00 |
DisclosureSEC source: 0001562180-18-001886 · primarydocument.xml · nonDerivative · entry 1 Christmas Patrick J. · CIK 0001521123 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,141 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| January 03, 2018 Filed Jan 5, 2018 22:04 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantStock Option (Right to Buy) · Derivative | 43,000 | $0.00 Strike: $35.80 | $0.00 |
DisclosureSEC source: 0001562180-18-000243 · primarydocument.xml · derivative · entry 3 Christmas Patrick J. · CIK 0001521123 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,000 Underlying: Common Stock · 43,000 shares Expires 2028-01-03 F5 · derivative.exercise_date: 25% of the shares subject to this option shall vest after 12 months of continuous service with the Issuer. The balance will vest in equal monthly installments over the 36 months following January 3, 2019 while the optionee provides continuous service to the Issuer. Read SEC document |
| December 29, 2017 Filed Jan 5, 2018 22:04 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantCommon Stock | 486 | $17.43 | $8,468.55 |
DisclosureSEC source: 0001562180-18-000243 · primarydocument.xml · nonDerivative · entry 2 Christmas Patrick J. · CIK 0001521123 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,141 F3 · security: The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the ESPP for the ESPP purchase period of July 1, 2017 through December 31, 2017. This transaction is exempt under Rule 16b-3(c). F4 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on July 3, 2017. Read SEC document |
| June 30, 2017 Filed Jan 5, 2018 22:04 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantCommon Stock | 655 | $15.73 | $10,299.88 |
DisclosureSEC source: 0001562180-18-000243 · primarydocument.xml · nonDerivative · entry 1 Christmas Patrick J. · CIK 0001521123 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 655 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the REGENXBIO Inc. Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of January 1, 2017 through June 30, 2017. This transaction is exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on January 3, 2017. Read SEC document |
| January 04, 2017 Filed Jan 6, 2017 22:03 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantStock Option (Right to Buy) · Derivative | 11,100 | $0.00 Strike: $19.50 | $0.00 |
DisclosureSEC source: 0000899243-17-000699 · doc4.xml · derivative · entry 1 Christmas Patrick J. · CIK 0001521123 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,100 Underlying: Common Stock · 11,100 shares Expires 2027-01-03 F1 · derivative.exercise_date: 25% of the shares subject to this option shall vest after 12 months of continuous service with the Issuer. The balance will vest in equal monthly installments over the 36 months following 1/4/2018 while the optionee provides continuous service to the Issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.